Share

COVID-19 Drives Innovations in Diabetes Treatment and Care

The COVID-19 pandemic has jumpstarted innovation in healthcare delivery and allowed for real-world testing of diabetes care models in unprecedented ways, according to a manuscript published in The Journal of Clinical Endocrinology & Metabolism. For diabetes, which affects half a billion people worldwide, innovation has long been overdue. Currently, less than 50% of people with...
Share

Insulin Titration Software Combined with CGM Enables Patients with Diabetes to Improve Time in Range

First study to utilize CGM data with FDA-cleared, cloud-based titration software suggests significantly improved outcomes for patients while optimizing clinical resources This past summer, Glytec published the first proof-of-concept study that combines FDA-cleared remote insulin titration software and data from continuous glucose monitoring (CGM) systems. Results of the study, presented at the American Diabetes Association’s...
Share

Dexcom Signs Multi-Year Collaboration Agreement with the University of Virginia to Advance Type 1 and Type 2 Diabetes Research

Dexcom last month announced it has signed a five-year collaboration agreement with the University of Virginia to advance its research and development efforts on continuous glucose monitoring-based solutions. The research partnership will center on advancing Dexcom’s automated insulin delivery technology and exploring the use of continuous glucose monitoring tools outside the type 1 diabetes market,...
Share

Endocrine Society Partners with Beyond Type 1 to Address Immediate Needs of People Struggling to Access Insulin

A new tool for anyone in the United States struggling to access life-sustaining insulin launched today at GetInsulin.org. Created by global diabetes nonprofit organization Beyond Type 1, GetInsulin.org connects people with diabetes who take insulin to assistance programs and low-cost solutions that match their unique situation. Insulin is a life-essential medicine for over seven million people with...
Share

Positive Topline Results Announced in Type 1 Diabetes Clinical Trial

A clinical trial investigating a possible novel treatment of early-onset type 1 diabetes last month met the primary endpoint assessing the safety and tolerability of a new class of microbe-based therapeutic agents. Precigen ActoBio is evaluating this therapy — AG019 ActoBiotics — as a monotherapy and in combination with teplizumab. AG019 is formulated as an...
Share

Artificial Pancreas Can Prevent Dangerously Low Blood Sugar in People with Type 1 Diabetes

New system reduces the risk of exercise-related hypoglycemia A new artificial pancreas system can prevent hypoglycemia—episodes of dangerously low blood sugar—during and after heavy exercise in people with type 1 diabetes, according to a small study published in The Journal of Clinical Endocrinology & Metabolism. Despite advances in treatment, blood sugar control in type 1 diabetes remains challenging. The artificial pancreas has the potential to...
Share

Lilly Launches Initiative “Know Before the Low” to Help Patients with Diabetes Recognize and Share Symptoms

Singer/songwriter Crystal Bowersox kicks off the educational initiative by encouraging people to educate their support network and develop a plan for low blood sugar and very low blood sugar emergencies Eli Lilly and Company launched a new initiative earlier this summer to raise awareness about being prepared for these unpredictable conditions. With Know Before the...
Share

Next-Generation Integrated Continuous Glucose Monitor Now Available Following FDA Clearance

An integrated continuous glucose monitor (iCGM) is now available for adults and now children (4+ years) living with diabetes, following its clearance in June from the U.S. Food and Drug Administration (FDA). Abbot is marketing this new technology as the FreeStyle® Libre 2. The FreeStyle Libre 2 system uses Bluetooth to automatically alerts users when...